TP53

TP53. It is a crucial tumor suppressor gene that plays a fundamental role in preventing cancer development. Often described as "the guardian of the genome," it encodes the p53 protein, a transcription factor that regulates the expression of numerous target genes involved in critical cellular processes. Its proper function is essential for maintaining genomic stability and eliminating potentially cancerous cells.

Structure and function

The gene is located on the short arm of chromosome 17 at band p13.1. The encoded p53 protein is a phosphoprotein comprising several key functional domains, including a central DNA-binding domain that recognizes specific response elements in target genes. Under normal physiological conditions, the protein is maintained at low levels, primarily through its interaction with the E3 ubiquitin ligase MDM2, which targets it for proteasomal degradation. When activated by various forms of cellular stress, such as DNA damage, oncogene activation, or hypoxia, the protein undergoes post-translational modifications including phosphorylation and acetylation, leading to its stabilization and tetramerization. This active form then binds to DNA and regulates the transcription of a vast network of genes involved in cell cycle arrest, DNA repair, apoptosis, and senescence.

Role in cancer

The gene's role as a central tumor suppressor is underscored by its frequent inactivation in a wide spectrum of human malignancies. Its activation in response to genomic instability serves as a critical barrier to tumorigenesis. By initiating cell cycle arrest, it allows time for the activation of DNA repair mechanisms mediated by proteins like those in the nucleotide excision repair pathway. If damage is irreparable, it can promote programmed cell death or apoptosis through the upregulation of pro-apoptotic factors such as BAX and PUMA, thereby eliminating damaged cells. Furthermore, it can induce cellular senescence, a permanent state of growth arrest, preventing the proliferation of precancerous cells. Loss of these protective functions is a hallmark of cancer, allowing for the accumulation of mutations and uncontrolled cell division.

Mutations and variants

Inactivation of this gene occurs most commonly through missense mutations within the DNA-binding domain, which impair the protein's ability to bind to its target sequences. These mutations are frequently found in common cancers such as breast cancer, lung cancer, colorectal cancer, and ovarian cancer. Certain mutations, known as hotspot mutations, occur at specific codons like R175, R248, R273, and R282, and often confer a dominant-negative effect or a gain-of-function phenotype. Germline mutations in this gene are responsible for Li-Fraumeni syndrome, a rare autosomal dominant disorder that predisposes individuals to a wide range of early-onset cancers. Beyond point mutations, inactivation can also occur through deletion, frameshift mutation, or interaction with viral oncoproteins like the E6 protein of human papillomavirus.

Regulation and interactions

The activity and stability of the encoded protein are tightly regulated by a complex network of interactions. Its primary negative regulator is MDM2, which forms an autoregulatory feedback loop. The ARF protein, encoded by the CDKN2A locus, can inhibit MDM2, thereby stabilizing p53. Key upstream kinases that activate it in response to DNA damage include ATM, ATR, and CHK2, which are central components of the DNA damage response. The protein also interacts with numerous coactivators, such as p300 and CBP, which acetylate it to enhance its transcriptional activity. Furthermore, its function and degradation are modulated by other proteins including HAUSP, Pirh2, and COP1. Its role intersects with major signaling pathways like the PI3K/AKT/mTOR pathway and the Wnt signaling pathway.

Clinical significance

The near-universal involvement of this pathway in cancer makes it a prime target for therapeutic intervention. Restoring wild-type function in tumors is a major goal, pursued through strategies like small molecules that reactivate mutant p53, such as APR-246. Other approaches aim to inhibit the MDM2-p53 interaction using nutlin analogs or to exploit synthetic lethality in p53-deficient cells. The mutational status of this gene is a significant prognostic marker in many cancers, including chronic lymphocytic leukemia and serous ovarian carcinoma, and can influence treatment response. Its role extends beyond oncology, with implications in neurodegenerative diseases like Alzheimer's disease, ischemia-reperfusion injury, and aging. Research continues to explore its functions in metabolism, ferroptosis, and the tumor microenvironment. Category:Genes on human chromosome 17 Category:Tumor suppressor genes